The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1659
ISSUE1659
September 19, 2022
Lipid-Lowering Drugs
| Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Lipid-Lowering Drugs
September 19, 2022 (Issue: 1659)
Cholesterol management guidelines from the
American College of Cardiology/American Heart
Association Task Force were last published in 2019.
- SM Grundy et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. J Am Coll Cardiol 2019; 73:e285.
- US Preventive Services Task Force. Statin use for the primary prevention of cardiovascular disease in adults. US Preventive Services Task Force recommendation statement. JAMA 2022; 328:746.
- F Rodriguez et al. Association between intensity of statin therapy and mortality in patients with atherosclerotic cardiovascular disease. JAMA Cardiol 2017; 2:47.
- CB Newman et al. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol 2019; 39:e38.
- Cholesterol Treatment Trialists’ Collaboration. Effect of statin therapy on muscle symptoms: an individual participant meta-analysis of large-scale, randomised, double-blind trials. Lancet 2022 August 29 (epub).
- JG Robinson. Statins and diabetes risk: how real is it and what are the mechanisms? Curr Opin Lipidol 2015; 26:228.
- DB Rosoff et al. Mendelian randomization study of PCSK9 and HMG-CoA reductase inhibition and cognitive function. J Am Coll Cardiol 2022; 80:653.
- Inhibitors and inducers of CYP enzymes, P-glycoprotein, and other transporters. Med Lett Drugs Ther 2021 October 20 (epub). Available at: medicalletter.org/downloads/CYP_PGP_Tables.pdf.
- BS Wiggins et al. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2016; 134:e468.
- The AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365:2255.
- Drug interaction: dabigatran (Pradaxa) and statins. Med Lett Drugs Ther 2017; 59:26.
- FDA Drug Safety Communication. FDA requests removal of strongest warning against using cholesterol-lowering statins during pregnancy; still advises most pregnant patients should stop taking statins. August 30, 2021. Available at: https://bit.ly/3A6cvlN. Accessed August 31, 2022.
- MG Silverman et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA 2016; 316:1289.
- Pitavastatin (Livalo) – the seventh statin. Med Lett Drugs Ther 2010; 52:57.
- In brief: Pitavastatin magnesium (Zypitamag) for hyperlipidemia. Med Lett Drugs Ther 2018; 60:106.
- CP Cannon et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372:2387.
- B-K Kim et al. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomized, open-label, non-inferiority trial. Lancet 2022; 400:380.
- Alirocumab (Praluent) to lower LDL-cholesterol. Med Lett Drugs Ther 2015; 57:113.
- Evolocumab (Repatha) – a second PCSK9 inhibitor to lower LDL-cholesterol. Med Lett Drugs Ther 2015; 57:140.
- JG Robinson et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372:1489.
- MS Sabatine et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376:1713.
- AF Schmidt et al. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev 2020; 10:CD011748.
- L Raber et al. Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial. JAMA 2022; 327:1771.
- SJ Nicholls et al. Effect of evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction. JACC Cardiovasc Imaging 2022; 15:1308.
- RP Giugliano et al. Cognitive function in a randomized trial of evolocumab. N Engl J Med 2017; 377:633.
- PD Harvey et al. No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized phase 2 and 3 controlled trials: a meta-analysis of individual patient data. Eur Heart J 2018; 39:374.
- Z Yuan. Dysregulated expressions of PCSK9 are associated with neural tube defects. Atherosclerosis Supplements 2018; 32:143.
- RN Jerome et al. Using human ‘experiments of nature’ to predict drug safety issues: an example with PCSK9 inhibitors. Drug Saf 2018; 41:303.
- Inclisiran (Leqvio) for LDL-cholesterol lowering. Med Lett Drugs Ther 2022; 64:43.
- KK Ray et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med 2020; 382:1507.
- FJ Raal et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med 2020; 382:1520.
- DM Lloyd-Jones et al. 2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2022 August 25 (epub).
- Fish oil supplements. Med Lett Drugs Ther 2012; 54:83.
- Risk and Prevention Study Collaborative Group. n-3 fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med 2013; 368:1800.
- JE Manson et al. Marine n-3 fatty acids and prevention of cardiovascular disease and cancer. N Engl J Med 2019; 380:23.
- DL Bhatt et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med 2019; 380:11.
- PM Ridker et al. Effects of randomized treatment with icosapent ethyl and a mineral oil comparator on interleukin 1-β, interleukin-6, C-reactive protein, oxidized low-density lipoprotein cholesterol, homocysteine, lipoprotein(a), and lipoprotein-associated phospholipase A2: a REDUCE-IT biomarker substudy. Circulation 2022; 146:372.
- RA Harrington. Trials and tribulations of randomized clinical trials. Circulation 2022; 146:380.
- B Gencer et al. Effects of long-term marine Ώ-3 fatty acids supplementation on the risk of atrial fibrillation in randomized controlled trials of cardiovascular outcomes: a systematic review and meta-analysis. Circulation 2021; 144:1981.
- Bempedoic acid (Nexletol) for lowering LDL cholesterol. Med Lett Drugs Ther 2020; 62:53.
- KK Ray et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med 2019; 380:1022.
- AC Goldberg et al. The effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR Wisdom randomized clinical trial. JAMA 2019; 322:1780.
- CM Ballantyne et al. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiol 2020; 27:593.
- Drugs for hypertriglyceridemia. Med Lett Drugs Ther 2013; 55:17.
- HB Rubins et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999; 341:410.
- P Willeit et al. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. Lancet 2018; 392:1311.
- HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 2014; 371:203.
- FJ Raal et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet 2015; 385:341.
- Two new drugs for homozygous familial hypercholesterolemia. Med Lett Drugs Ther 2013; 55:25.
- FJ Raal et al. Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med 2020; 383:711.
- Evinacumab (Evkeeza) for homozygous familial hypercholesterolemia. Med Lett Drugs Ther 2021; 63:66.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Lipid-Lowering Drugs
Article code: 1659a
Article code: 1659a
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.